Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy
CONCLUSION: We successfully established a predictive model and diagnosis-treatment process using the RGT strategy to predict HBeAg and HBsAg seroconversion in patients with HBeAg-positive CHB undergoing PEG-IFNα therapy.PMID:38577530 | PMC:PMC10989310 | DOI:10.4254/wjh.v16.i3.405 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Pei-Xin Zhang Xiao-Wei Zheng Ya-Fei Zhang Jun Ye Wei Li Qian-Qian Tang Jie Zhu Gui-Zhou Zou Zhen-Hua Zhang Source Type: research
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
CONCLUSION: Hepatic steatosis lowers the biochemical response to antiviral treatment in patients with CHB.PMID:38577526 | PMC:PMC10989305 | DOI:10.4254/wjh.v16.i3.465 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Shi-Yi Liu Dian Wang Jing Liu Lu-Ping Yang Gong-Ying Chen Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine)
Source: Molecular Medicine - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
Trends in the prevalence of multiple chronic conditions among US adults with hypertension from 1999-2000 through 2017-2020
CONCLUSION: In 2017-2020, more than half of US adults with hypertension had ≥3 additional chronic conditions, a substantial increase from 20 years ago.PMID:38576398 | DOI:10.1093/ajh/hpae040 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - April 5, 2024 Category: Cardiology Authors: Chibuike J Alanaeme Lama Ghazi Oluwasegun P Akinyelure Ying Wen Ashley Christenson Bharat Poudel Erin E Dooley Ligong Chen Shakia T Hardy Kathryn Foti C Barrett Bowling Michelle T Long Lisandro D Colantonio Paul Muntner Source Type: research
Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis
World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. doi: 10.3748/wjg.v30.i9.1253.ABSTRACTHepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient's underlying tumor and the specific malignancy type ...
Source: World Journal of Gastroenterology : WJG - April 5, 2024 Category: Gastroenterology Authors: Francesca Colapietro Nicola Pugliese Antonio Voza Alessio Aghemo Stella De Nicola Source Type: research
Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review
Medicine (Baltimore). 2024 Apr 5;103(14):e37653. doi: 10.1097/MD.0000000000037653.ABSTRACTRATIONALE: Primary myelofibrosis is a subtype of myeloproliferative neoplasm that leads to bone marrow fibrosis. Historically, the only curative option for primary myelofibrosis was allogeneic hematopoietic stem cell transplant. Ruxolitinib, a Janus kinase inhibitor, is now used for the treatment of primary myelofibrosis and polycythemia vera. It effectively improves symptoms related to splenomegaly and anemia. However, its association with the development of opportunistic infections has been observed in clinical studies and practical...
Source: Herpes - April 5, 2024 Category: Infectious Diseases Authors: Chi-Yu Chen Tun-Chieh Chen Source Type: research
Management strategies for common viral infections in pediatric renal transplant recipients
World J Transplant. 2024 Mar 18;14(1):89978. doi: 10.5500/wjt.v14.i1.89978.ABSTRACTViral infections have been considered as a major cause of morbidity and mortality after kidney transplantation in pediatric cohort. Children are at high risk of acquiring virus-related complications due to immunological immaturity and the enhanced alloreactivity risk that led to maintenance of high immunosuppressive regimes. Hence, prevention, early detection, and prompt treatment of such infe ctions are of paramount importance. Among all viral infections, herpes viruses (herpes simplex virus, varicella zoster virus, Epstein-Barr virus, cyto...
Source: Herpes - April 5, 2024 Category: Infectious Diseases Authors: Randula Ranawaka Kavinda Dayasiri Erandima Sandamali Manoji Gamage Source Type: research
Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis
World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. doi: 10.3748/wjg.v30.i9.1253.ABSTRACTHepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient's underlying tumor and the specific malignancy type ...
Source: World Journal of Gastroenterology - April 5, 2024 Category: Gastroenterology Authors: Francesca Colapietro Nicola Pugliese Antonio Voza Alessio Aghemo Stella De Nicola Source Type: research
Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
World J Hepatol. 2024 Mar 27;16(3):331-343. doi: 10.4254/wjh.v16.i3.331.ABSTRACTChronic hepatitis B virus (HBV) infection affects over 295 million people globally and an estimated 1.6 million people in the United States. It is associated with significant morbidity and mortality due to cirrhosis, liver failure, and liver cancer. Antiviral therapy with oral nucleos(t)ide analogues is associated with high rates of virologic suppression, which in turn has been associated with a decreased risk of liver complications. However, current antiviral regimens are limited by concerns with adverse effects, adherence, resistance, long-te...
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Robert Lam Joseph K Lim Source Type: research
Is there a need for universal double reflex testing of HBsAg-positive individuals for hepatitis D infection?
World J Hepatol. 2024 Mar 27;16(3):300-303. doi: 10.4254/wjh.v16.i3.300.ABSTRACTHepatitis D virus (HDV) can infect HBsAg-positive individuals, causing rapid fibrosis progression, early decompensation, increased hepatocellular carcinoma risk, and higher mortality than hepatitis B virus (HBV) mono-infection. Most countries lack high-quality HDV prevalence data, and the collection techniques employed often bias published data. In recent meta-analyses, HDV prevalence in HBsAg-positive patients reaches 5%-15% and is even significantly higher in endemic areas. Since HBV vaccination programs were implemented, HDV prevalence has d...
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Zaigham Abbas Minaam Abbas Source Type: research
Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy
CONCLUSION: We successfully established a predictive model and diagnosis-treatment process using the RGT strategy to predict HBeAg and HBsAg seroconversion in patients with HBeAg-positive CHB undergoing PEG-IFNα therapy.PMID:38577530 | PMC:PMC10989310 | DOI:10.4254/wjh.v16.i3.405 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Pei-Xin Zhang Xiao-Wei Zheng Ya-Fei Zhang Jun Ye Wei Li Qian-Qian Tang Jie Zhu Gui-Zhou Zou Zhen-Hua Zhang Source Type: research
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
CONCLUSION: Hepatic steatosis lowers the biochemical response to antiviral treatment in patients with CHB.PMID:38577526 | PMC:PMC10989305 | DOI:10.4254/wjh.v16.i3.465 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Shi-Yi Liu Dian Wang Jing Liu Lu-Ping Yang Gong-Ying Chen Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine)
Source: Molecular Medicine - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
Research progress on oncoprotein hepatitis B X ‑interacting protein (Review)
In conclusion, the present review summarized the existing knowledge of HBXIP, established its carcinogenic mechanism and discussed future related research on HBXIP.PMID:38577934 | DOI:10.3892/mmr.2024.13213 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - April 5, 2024 Category: Molecular Biology Authors: Lei Cheng Lijuan Guo Teng Zou Yisong Yang Ran Tao Shuangping Liu Source Type: research
